Company insight The ultimate dry ice shipper
Mike Bartone, VP, global cold chain solutions at Marken, UPS Healthcare Precision Logistics, and Sam Herbert, CEO at Peli BioThermal, give their thoughts on the dynamic Marken-Peli collaboration and the development of the innovative Marken InfiniDI packaging solution.
What areas of cold chain pharmaceutical packaging are advancing most rapidly and how can sponsors stay ahead? Mike Bartone: Advanced therapies, nuclear medicines and high-value biologics are shrinking stability windows, requiring longer, more predictable hold times – making packaging a critical risk- management tool. Real-time tracking now enables faster temperature reporting and predictive routing, while sustainability has become an operational mandate, driving a shift to reusable platforms, reverse logistics and reduced dry ice usage. To stay competitive, pharma stakeholders should standardise on multi-day dry ice performance with integrated real-time monitoring and lane validation, enabling faster, data-driven decision-making.
Sam Herbert: The fastest shift is from single-use to engineered, reusable systems qualified to standards like ISTA 7D, for reliable performance across varied climates and geographies. Collaboration across the supply chain is vital, enabling sponsors to align packaging innovation with the rapid pace of therapeutic innovation. To stay ahead, sponsors should focus on reusable platforms and strategic alliances that link scientific breakthroughs with supply chain advances, ensuring solutions are scalable and evolve with new treatments.
What was the driving force behind the Marken-Peli collaboration and the development of the Marken InfiniDI packaging solution? MB: The stringent demands of transporting precision medicines uncovered gaps in legacy cold chain packaging, which relied on heavy dry ice and frequent re-icing, increasing cost, carbon and complexity. Marken and Peli combined expertise to develop InfiniDI, the ultimate reusable, sustainable dry ice shipper – delivering extended temperature control with fewer interventions.
www.worldpharmaceuticals.net
SH: Our collaboration was born from a shared commitment to advancing both sustainability and reliability in the deep- frozen space. Uniting Marken’s precision logistics and Peli BioThermal’s proven thermal engineering, InfiniDI reduces re-icing touchpoints while ensuring life- saving products move safely and efficiently around the globe.
What engineering features set InfiniDI apart as a leading reusable dry ice shipper? SH: InfiniDI was engineered to combine unmatched thermal performance with sustainability at scale. Using VIP insulation, advanced thermal design, optimised airflow engineering and fully reusable construction, it maintains temperatures below -60°C for more than 144 hours, while using up to 50% less dry ice and cutting landfill waste by up to 90%. Each unit is ISTA 7D qualified and designed for lane validation, telemetry and continuous monitoring. By combining extended temperature stability, reduced dry ice usage, and a truly reusable design, InfiniDI sets the benchmark as the most advanced, sustainable and versatile dry ice shipper on the market today.
MB: Coupled with Marken’s global network, real-time visibility and built-in reverse logistics, InfiniDI containers are seamlessly retrieved, reconditioned and redeployed, cutting on-site clutter and waste. Fewer interventions mean faster speed-to-market and reliable lane performance. It’s a next- gen risk-management tool that protects high-value therapies while lowering cost and environmental impact.
How is InfiniDI deployed for clients and patients, and what real-world impact does it deliver? MB: As part of Marken’s Ready Now catalogue, InfiniDI is currently being deployed globally within Marken’s expansive logistics infrastructure, enabling rapid adoption and unmatched responsiveness to
fluctuating study demands. By removing re-icing delays and minimising Class-9 handling, sensitive therapies reach patients safely, on time, every time – even across complex, multi-leg routes. InfiniDI delivers reliability where it matters most: protecting dose availability, reducing risk and accelerating healthcare innovations from discovery to doorstep.
SH: InfiniDI provides sponsors with a trusted, sustainable solution that advances ESG goals – and most importantly, ensures life-saving medicines reach patients who need them most.
What will define the next generation of cold chain packaging, and are future innovations already on the horizon? SH: Solutions that balance sustainability with uncompromising performance. Through our partnership with Marken, we’re already delivering packaging that is greener, smarter and prepared to support the next wave of life-changing therapies. And the horizon is even brighter – Peli BioThermal is constantly seeking new ways to innovate as the needs of the industry, the world and patients continue to evolve.
MB: Sustainability, flexibility and intelligence. At Marken, we don’t rely on a single approach. Instead, our strategy combines bold innovation with scalable, proven solutions, guided by customer needs, patient experience and industry dynamics. Marken is enhancing reverse- logistics efficiency, and integrating real- time monitoring, predictive analytics and smart asset management into our platforms. Alongside InfiniDI, we’re developing innovations with greener materials to meet diverse client demands and push the boundaries of visibility and performance – ultimately improving outcomes for patients worldwide. ●
www.marken.com 63
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85
